ADMA Biologics Announces Presentation on Respiratory Viral Infections at IDWeek 2021
October 01 2021 - 7:00AM
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an
end-to-end commercial biopharmaceutical company dedicated to
manufacturing, marketing and developing specialty plasma-derived
biologics, today announced an exclusive educational event at IDWeek
2021 on respiratory viral infections, presented by nationally
recognized clinical experts Dr. Michael Ison from Northwestern
University and Dr. Jolan Walter from the University of South
Florida and Johns Hopkins All Children’s Hospital. Two leading
experts in the management of respiratory syncytial virus (RSV) and
other respiratory viruses in immunocompromised patients will
discuss today’s key clinical challenges and emerging treatment
strategies. A novel intravenous immunoglobulin (IVIG) product with
a unique composition will be introduced, including patient cases.
Educational Event Presentation Title: Key
Insights on RSV and Other Respiratory Viruses Beyond COVID-19 in
the Immunocompromised: An Expert Discussion
Session Date: Friday, October 1,
2021Session Time: 1:00 PM – 1:45 PM
ETSession Location: IDWeek Learning
Lounge
- Michael
G. Ison, MD, MS, Professor of Medicine (Infectious
Diseases) and Surgery (Organ Transplantation) at the Feinberg
School of Medicine at Northwestern University, will discuss
respiratory viruses in the immunocompromised, impact and management
strategies.
- Jolan
Walter, MD, PhD, Division Chief of the University of South
Florida (USF) and Johns Hopkins All Children’s Pediatric Allergy
& Immunology Programs, will discuss management modalities and
introduce ASCENIV™, a novel IVIG, and present clinical data and
case presentations.
About ASCENIV™
ASCENIV (immune globulin intravenous, human – slra 10% liquid)
is a plasma-derived, polyclonal, intravenous IVIG. ASCENIV was
approved by the United States Food and Drug Administration (FDA) in
April 2019 and is indicated for the treatment of primary humoral
immunodeficiency (PI), also known as primary immune deficiency
disease (PIDD), in adults and adolescents (12 to 17 years of age).
ASCENIV is manufactured using ADMA’s unique, patented plasma donor
screening methodology and tailored plasma pooling design, which
blends normal source plasma and RSV plasma obtained from donors
tested using the Company’s proprietary microneutralization assay.
ASCENIV contains naturally occurring polyclonal antibodies, which
are proteins that are used by the body’s immune system to
neutralize microbes, such as bacteria and viruses and prevent
against infection and disease. ASCENIV is protected by U.S.
Patents: 9,107,906, 9,714,283 and 9,815,886. Certain data and other
information about ASCENIV™ can be found by visiting
www.asceniv.com. Information about ADMA Biologics and its products
can be found on the Company’s website at www.admabiologics.com.
About ADMA Biologics, Inc.
(ADMA)
ADMA Biologics is an end-to-end commercial
biopharmaceutical company dedicated to manufacturing, marketing and
developing specialty plasma-derived biologics for the treatment of
immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures and
markets three United States Food and Drug Administration
(FDA-approved) plasma-derived biologics for the treatment of immune
deficiencies and the prevention of certain infectious diseases:
ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of primary humoral immunodeficiency (PI); BIVIGAM®
(immune globulin intravenous, human) for the treatment of PI; and
NABI-HB® (hepatitis B immune globulin, human) to provide enhanced
immunity against the hepatitis B virus. ADMA manufactures its
immune globulin products at its FDA-licensed plasma fractionation
and purification facility located in Boca Raton, Florida. Through
its ADMA BioCenters subsidiary, ADMA also operates as an
FDA-approved source plasma collector in the U.S., which provides a
portion of its blood plasma for the manufacture of its products.
ADMA’s mission is to manufacture, market and develop specialty
plasma-derived, human immune globulins targeted to niche patient
populations for the treatment and prevention of certain infectious
diseases and management of immune compromised patient populations
who suffer from an underlying immune deficiency, or who may be
immune compromised for other medical reasons. ADMA has received
U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 related to certain aspects of its products and product
candidates. For more information, please visit
www.admabiologics.com.
COMPANY CONTACT: Skyler BloomDirector, Investor
Relations and Corporate Strategy | 201-478-5552 |
sbloom@admabio.com
INVESTOR RELATIONS CONTACT:Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 |
michelle@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Apr 2023 to Apr 2024